|
|
 |
| Safety |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scientific opinions |
|
|
|
|
|
|
 |
TSE Advisory Committee of the FDA confirms the BSE Safety of Bone Gelatine
|
|
|
Following the submission of five validation studies which examined the manufacturing processes of bone gelatine (sponsored by GME and the European Union) the U.S. Food and Drug Administration (FDA), with the assistance of its TSE Advisory Committee (TSEAC), decided to re-consider the safety profile of bovine bone gelatine.
The studies showed that even in the practically impossible event that raw materials were taken only from BSE infected cattle, no BSE infectivity could be detected in the final gelatine produced by all different manufacturing processes.
The members of the TSEAC concluded that: The results of these new studies demonstrate that the gelatine manufacturing process has the capacity to reduce BSE infectivity that is sufficient to protect human health.
|
|
|
More... |
|
|
|
|
Updated Opinion of the European Commission |
|
|
Health & Consumer Protection Directorate-General
Scientific Steering Committee
"Updated opinion on the safety with regard to TSE risks of gelatine derived from ruminant bones or hides"
6-7 March 2003 |
|
Download (pdf-File, 2.3 MB) |
|
|
|
|
|
|
|
|
|
